Meta-analysis: Aspirin for cardiovascular primary prevention in patients with and without diabetes
According to a report published early online in Diabetes Care, the relative benefit of aspirin for primary prevention of cardiovascular events is similar in patients with and without diabetes.
This finding comes from a systematic review and meta-analysis, which set out to estimate the efficacy of aspirin for the primary prevention of cardiovascular events among patients with diabetes, and to estimate the extent to which the effect of aspirin differs in patients with and without diabetes.
Nine RCTs of aspirin for primary prevention of cardiovascular events with moderate to high methodological quality were identified. The ratios of relative risks of the benefit of aspirin among patients with diabetes compared to patients without diabetes for the following outcomes were reported:
The researchers conclude “while there are insufficient data among patients with diabetes to conclusively show a benefit of aspirin therapy for the primary prevention of cardiovascular events, our data suggest, but do not confirm, that the relative benefit of aspirin is similar in patients with and without diabetes. Additional evidence from RCTs and individual-patient-data meta-analyses may help to further clarify this issue.”
Diabetes Care, published early online 9 September 2009; doi: 10.2337/dc09-1297 (link to abstract)
11 September 2009
1 comment:
glipizide 10 mg It belongs to a group of medicines called sulfonylureas and helps control blood sugar levels in people with diabetes. It may also be used with other diabetes medications. This medication will only help lower blood sugar in people whose bodies produce insulin naturally.
Post a Comment